Curis, Inc.(CRIS): For the most recent quarter end, Curis, Inc. reported Annual Earnings of $-0.12. Based on the filings, last years Annual Earnings was, $-0.28. For the most recent quarter end, CRIS reported a surprise Earnings per Share of -20% . The consensus estimate for current quarter is $-0.08 and for the current fiscal year, the estimate is $-0.39. For the Next fiscal year, the estimate is $-0.36 based on the consensus.
Curis, Inc. has received $-0.08 as the consensus Earnings Estimate for the Quarter ending on Dec 2016 ,According to the estimate provided by 4 Financial Advisor in the Stock Trading Firms. Among 4 Analysts, Bottom line EPS Estimate for the current quarter is $-0.1 while the top line estimate is $-0.07 , a key information to consider for Day Trading and investing in stocks. The EPS growth rate is projected at 20%. Curis, Inc. results fell short with a surprise EPS of -20% or $-0.02. The Actual EPS was $-0.12 compared to the Estimated EPS of $-0.1 during its most recent quarterly earnings.
Curis Last issued its quarterly earnings results on Nov 3, 2016. The company reported $-0.21 EPS for the quarter, missing the analyst consensus estimate by $ -0.11. Analyst had a consensus of $-0.10. The company had revenue of $1.76 million for the quarter, compared to analysts expectations of $1.85 million. The companys revenue was down -14.1 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $-0.04 EPS.
Company has reported several Insider transactions to the SEC, on May 27, 2016, Martyn D Greenacre (director) sold 15,000 shares at 1.69 per share price.On May 27, 2016, Kenneth I Kaitin (director) sold 15,000 shares at 1.76 per share price.On Dec 30, 2015, Daniel R Passeri (director) sold 25,600 shares at 2.96 per share price.
Curis, Inc. (NASDAQ:CRIS) witnessed a decline in the market cap on Wednesday as its shares dropped 4.89% or 0.13 points. After the session commenced at $2.66, the stock reached the higher end at $2.7 while it hit a low of $2.5. With the volume soaring to 611,977 shares, the last trade was called at $2.53. The company has a 52-week high of $3.72. The company has a market cap of $356 million and there are 140,549,020 shares in outstanding. The 52-week low of the share price is $1.34.
Curis, Inc. is a therapeutic drug development company focusing on cancer, neurological and dermatological disease indications, with technologies that utilize regulatory pathways that control repair and regeneration. Curis product development involves the use of small molecules or proteins to modulate these pathways. The company has successfully used this technology and product development approach to produce several promising drug product candidates in the fields of cancer, neurological disorders, hair growth, kidney and other diseases, as well as cardiovascular disease.